Table 1 Prospective noncontrolled... | American Society of Hematology

Table 1

Prospective noncontrolled response-adapted studies in adult early-stage (I-II) HL

Trial	Patients	Treatment	Number	Interim PET⁺	PPV	NPV	Survival
Le Roux et al, 2011²⁸	Stages I-IV	ABVD × 4 (FDG-PET): I/II nonbulky: PET⁻ and/or CR on CT IFRT; PET⁺ SCT II bulky/III/IV: PET⁻ ABVD × 4; PET⁺ SCT	90 (45 stage I/II)	34% (all patients)	16% (all patients)	95% (all patients)	NA
Dann et al, 2013⁴⁰	Stage I-IIA-B nonbulky	ABVD × 2 (FDG-PET): favorable: PET⁻ INRT; PET⁺ ABVD × 2 + INRT (PET 4)* Unfavorable: PET⁻ ABVD × 2 + INRT; PET⁺ ABVD × 4 + INRT (PET 4)*	350/350†	13%	26%	93%	2-y PFS 94%
CALGB 50604 (NCT01132807)	Stage I/IIA-B nonbulky	ABVD × 2 (FDG-PET): PET⁻ ABVD × 2 PET⁺ BEACOPP-escalated × 2 + 30Gy IFRT	160/160	Accrual completed February 2013; preliminary results expected 2015
CALGB 50801 (NCT01118026)	Stage I/IIA-B bulky	ABVD × 2 (FDG-PET): PET⁻ ABVD × 4 PET⁺ BEACOPP-escalated × 4 + 30Gy IFRT	53/123†	NA

Trial	Patients	Treatment	Number	Interim PET⁺	PPV	NPV	Survival
Le Roux et al, 2011²⁸	Stages I-IV	ABVD × 4 (FDG-PET): I/II nonbulky: PET⁻ and/or CR on CT IFRT; PET⁺ SCT II bulky/III/IV: PET⁻ ABVD × 4; PET⁺ SCT	90 (45 stage I/II)	34% (all patients)	16% (all patients)	95% (all patients)	NA
Dann et al, 2013⁴⁰	Stage I-IIA-B nonbulky	ABVD × 2 (FDG-PET): favorable: PET⁻ INRT; PET⁺ ABVD × 2 + INRT (PET 4)* Unfavorable: PET⁻ ABVD × 2 + INRT; PET⁺ ABVD × 4 + INRT (PET 4)*	350/350†	13%	26%	93%	2-y PFS 94%
CALGB 50604 (NCT01132807)	Stage I/IIA-B nonbulky	ABVD × 2 (FDG-PET): PET⁻ ABVD × 2 PET⁺ BEACOPP-escalated × 2 + 30Gy IFRT	160/160	Accrual completed February 2013; preliminary results expected 2015
CALGB 50801 (NCT01118026)	Stage I/IIA-B bulky	ABVD × 2 (FDG-PET): PET⁻ ABVD × 4 PET⁺ BEACOPP-escalated × 4 + 30Gy IFRT	53/123†	NA

SCT, stem cell transplantation; and NA, not available.

Biopsy done if PET-4 is positive; patients receive same therapy as PET-4⁻ for negative biopsy and salvage therapy for positive PET-4 biopsy.

Enrollment as of June 2014. Of enrolled patients, 173 have early-stage disease.